Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 348

1.

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.

Drugs. 2019 Feb 2. doi: 10.1007/s40265-019-1055-2. [Epub ahead of print] Review.

PMID:
30712199
2.

Frequency of 16S ribosomal RNA methyltransferase detection among Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013-2017).

Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Boyd D, Bharat A, Mulvey MR, Charles M, Bergevin M, Zhanel GG.

Diagn Microbiol Infect Dis. 2018 Dec 14. pii: S0732-8893(18)30684-9. doi: 10.1016/j.diagmicrobio.2018.12.005. [Epub ahead of print]

PMID:
30638654
3.

Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study.

Denisuik AJ, Garbutt LA, Golden AR, Adam HJ, Baxter M, Nichol KA, Lagacé-Wiens P, Walkty AJ, Karlowsky JA, Hoban DJ, Mulvey MR, Zhanel GG.

J Antimicrob Chemother. 2019 Mar 1;74(3):645-653. doi: 10.1093/jac/dky477.

PMID:
30500898
4.

In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli.

Karlowsky JA, Adam HJ, Baxter MR, Denisuik AJ, Lagacé-Wiens PRS, Walkty AJ, Puttagunta S, Dunne MW, Zhanel GG.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01832-18. doi: 10.1128/AAC.01832-18. Print 2019 Jan.

PMID:
30397056
5.

Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris.

Zhanel G, Critchley I, Lin LY, Alvandi N.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01297-18. doi: 10.1128/AAC.01297-18. Print 2019 Jan.

6.

Dilipid ultrashort cationic lipopeptides as adjuvants for chloramphenicol and other conventional antibiotics against Gram-negative bacteria.

Domalaon R, Brizuela M, Eisner B, Findlay B, Zhanel GG, Schweizer F.

Amino Acids. 2018 Nov 3. doi: 10.1007/s00726-018-2673-9. [Epub ahead of print]

PMID:
30392097
7.

In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study.

Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Zhanel GG.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e02068-18. doi: 10.1128/AAC.02068-18. Print 2019 Jan.

PMID:
30373806
8.

Development of dilipid polymyxins: Investigation on the effect of hydrophobicity through its fatty acyl component.

Domalaon R, Berry L, Tays Q, Zhanel GG, Schweizer F.

Bioorg Chem. 2018 Oct;80:639-648. doi: 10.1016/j.bioorg.2018.07.018. Epub 2018 Jul 19.

PMID:
30053708
9.

Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada.

Zhanel GG, Zhanel MA, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2018 Jun 25;2018:8912039. doi: 10.1155/2018/8912039. eCollection 2018. Review.

10.

Molecular characterization of predominant Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011-15.

Golden AR, Adam HJ, Karlowsky JA, Baxter M, Nichol KA, Martin I, Demczuk W, Van Caeseele P, Gubbay JB, Lefebvre B, Levett PN, Zahariadis G, Haldane D, Gad R, German G, Gilmour MW, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii20-vii31. doi: 10.1093/jac/dky157.

PMID:
29982573
11.

Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-15.

Adam HJ, Golden AR, Karlowsky JA, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii12-vii19. doi: 10.1093/jac/dky158.

PMID:
29982572
12.
13.

Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-15.

Karlowsky JA, Adam HJ, Golden AR, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii5-vii11. doi: 10.1093/jac/dky156.

PMID:
29982570
14.

Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010-2016.

Demczuk WHB, Martin I, Desai S, Griffith A, Caron-Poulin L, Lefebvre B, McGeer A, Tyrrell GJ, Zhanel GG, Gubbay J, Hoang L, Levett PN, Van Caeseele P, Raafat Gad R, Haldane D, Zahariadis G, German G, Daley Bernier J, Strudwick L, Mulvey MR.

Vaccine. 2018 Jul 25;36(31):4701-4707. doi: 10.1016/j.vaccine.2018.06.018. Epub 2018 Jun 21.

PMID:
29937245
15.

Tobramycin-Linked Efflux Pump Inhibitor Conjugates Synergize Fluoroquinolones, Rifampicin and Fosfomycin against Multidrug-Resistant Pseudomonas aeruginosa.

Yang X, Domalaon R, Lyu Y, Zhanel GG, Schweizer F.

J Clin Med. 2018 Jun 22;7(7). pii: E158. doi: 10.3390/jcm7070158.

16.

Correction to: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2018 May;78(7):787. doi: 10.1007/s40265-018-0910-x.

PMID:
29748749
17.

Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli.

Zhanel GG, Zhanel MA, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2018 Jan 30;2018:1404813. doi: 10.1155/2018/1404813. eCollection 2018. Review.

18.

Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis.

Zelenitsky SA, Beahm NP, Iacovides H, Ariano RE, Zhanel G.

J Antimicrob Chemother. 2018 Jul 1;73(7):1888-1894. doi: 10.1093/jac/dky120.

PMID:
29635472
19.

Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?

Domalaon R, Idowu T, Zhanel GG, Schweizer F.

Clin Microbiol Rev. 2018 Mar 14;31(2). pii: e00077-17. doi: 10.1128/CMR.00077-17. Print 2018 Apr. Review.

PMID:
29540434
20.

PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium difficile Surveillance Study (CAN-DIFF) 2013-2015.

Karlowsky JA, Adam HJ, Kosowan T, Baxter MR, Nichol KA, Laing NM, Golding G, Zhanel GG.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):105-111. doi: 10.1016/j.diagmicrobio.2018.01.017. Epub 2018 Jan 31.

PMID:
29456070
21.

Short Proline-Rich Lipopeptide Potentiates Minocycline and Rifampin against Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa.

Domalaon R, Sanchak Y, Koskei LC, Lyu Y, Zhanel GG, Arthur G, Schweizer F.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02374-17. doi: 10.1128/AAC.02374-17. Print 2018 Apr.

22.

In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015.

Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky JA.

Diagn Microbiol Infect Dis. 2018 May;91(1):55-62. doi: 10.1016/j.diagmicrobio.2017.12.013. Epub 2017 Dec 22.

PMID:
29338931
23.

In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.

Walkty A, Adam H, Baxter M, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2018 Mar 1;73(3):703-708. doi: 10.1093/jac/dkx468.

PMID:
29244121
24.

Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9. Review. Erratum in: Drugs. 2018 May 10;:.

PMID:
29230684
25.

Biocide Selective TolC-Independent Efflux Pumps in Enterobacteriaceae.

Slipski CJ, Zhanel GG, Bay DC.

J Membr Biol. 2018 Feb;251(1):15-33. doi: 10.1007/s00232-017-9992-8. Epub 2017 Oct 23.

26.

Polymyxin B3-Tobramycin Hybrids with Pseudomonas aeruginosa-Selective Antibacterial Activity and Strong Potentiation of Rifampicin, Minocycline, and Vancomycin.

Domalaon R, Yang X, Lyu Y, Zhanel GG, Schweizer F.

ACS Infect Dis. 2017 Dec 8;3(12):941-954. doi: 10.1021/acsinfecdis.7b00145. Epub 2017 Oct 27.

PMID:
29045123
27.

Emergence of Antimicrobial Resistance among Pseudomonas aeruginosa: Implications for Therapy.

Lynch JP 3rd, Zhanel GG, Clark NM.

Semin Respir Crit Care Med. 2017 Jun;38(3):326-345. doi: 10.1055/s-0037-1602583. Epub 2017 Jun 4. Review.

PMID:
28578556
28.

Infections Due to Acinetobacter baumannii in the ICU: Treatment Options.

Lynch JP 3rd, Zhanel GG, Clark NM.

Semin Respir Crit Care Med. 2017 Jun;38(3):311-325. doi: 10.1055/s-0037-1599225. Epub 2017 Jun 4.

PMID:
28578555
29.

Phylogenetic analysis of emergent Streptococcus pneumoniae serotype 22F causing invasive pneumococcal disease using whole genome sequencing.

Demczuk WHB, Martin I, Hoang L, Van Caeseele P, Lefebvre B, Horsman G, Haldane D, Gubbay J, Ratnam S, German G, Daley Bernier J, Strudwick L, McGeer A, Zhanel GG, Van Domselaar G, Graham M, Mulvey MR.

PLoS One. 2017 May 22;12(5):e0178040. doi: 10.1371/journal.pone.0178040. eCollection 2017.

30.

Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential.

Lagacé-Wiens PRS, Adam HJ, Laing NM, Baxter MR, Martin I, Mulvey MR, Karlowsky JA, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2017 Aug 1;72(8):2273-2277. doi: 10.1093/jac/dkx147.

PMID:
28505331
31.

Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model.

Zhanel GG, Parkinson K, Higgins S, Denisuik A, Adam H, Pitout J, Noreddin A, Karlowsky JA.

Diagn Microbiol Infect Dis. 2017 Jul;88(3):271-275. doi: 10.1016/j.diagmicrobio.2017.04.007. Epub 2017 Apr 23.

PMID:
28483306
32.

Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.

Lyu Y, Yang X, Goswami S, Gorityala BK, Idowu T, Domalaon R, Zhanel GG, Shan A, Schweizer F.

J Med Chem. 2017 May 11;60(9):3684-3702. doi: 10.1021/acs.jmedchem.6b01742. Epub 2017 Apr 24.

PMID:
28409644
33.

A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.

Yang X, Goswami S, Gorityala BK, Domalaon R, Lyu Y, Kumar A, Zhanel GG, Schweizer F.

J Med Chem. 2017 May 11;60(9):3913-3932. doi: 10.1021/acs.jmedchem.7b00156. Epub 2017 Apr 24.

PMID:
28399372
34.

Antimicrobial susceptibility of 2906 Pseudomonasaeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015.

Walkty A, Lagace-Wiens P, Adam H, Baxter M, Karlowsky J, Mulvey MR, McCracken M, Zhanel GG.

Diagn Microbiol Infect Dis. 2017 Jan;87(1):60-63. doi: 10.1016/j.diagmicrobio.2016.10.003. Epub 2016 Oct 7.

PMID:
28336136
35.

Cost-Effectiveness Analysis of Fosfomycin for Treatment of Uncomplicated Urinary Tract Infections in Ontario.

Perrault L, Dahan S, Iliza AC, LeLorier J, Zhanel GG.

Can J Infect Dis Med Microbiol. 2017;2017:6362804. doi: 10.1155/2017/6362804. Epub 2017 Feb 20.

36.

In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.

Karlowsky JA, Walkty AJ, Baxter MR, Arhin FF, Moeck G, Adam HJ, Zhanel GG.

Diagn Microbiol Infect Dis. 2017 Apr;87(4):349-356. doi: 10.1016/j.diagmicrobio.2017.01.006. Epub 2017 Jan 20.

PMID:
28159446
37.

Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015).

Walkty A, Karlowsky JA, Adam HJ, Lagacé-Wiens P, Baxter M, Mulvey MR, McCracken M, Poutanen SM, Roscoe D, Zhanel GG.

CMAJ Open. 2016 Oct 26;4(4):E641-E645. doi: 10.9778/cmajo.20160080. eCollection 2016 Oct-Dec.

38.

Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.

Zhanel GG, Hartel E, Adam H, Zelenitsky S, Zhanel MA, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty AJ, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2016 Dec;76(18):1737-1757. Review.

PMID:
27909995
39.

Emergence of antimicrobial resistance among Acinetobacter species: a global threat.

Clark NM, Zhanel GG, Lynch JP 3rd.

Curr Opin Crit Care. 2016 Oct;22(5):491-9. doi: 10.1097/MCC.0000000000000337. Review.

PMID:
27552304
40.

Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.

Gorityala BK, Guchhait G, Goswami S, Fernando DM, Kumar A, Zhanel GG, Schweizer F.

J Med Chem. 2016 Sep 22;59(18):8441-55. doi: 10.1021/acs.jmedchem.6b00867. Epub 2016 Aug 30.

PMID:
27524179
42.

Integrated pharmacokinetic-pharmacodynamic modelling to evaluate antimicrobial prophylaxis in abdominal surgery.

Zelenitsky SA, Lawson C, Calic D, Ariano RE, Roberts JA, Lipman J, Zhanel GG.

J Antimicrob Chemother. 2016 Oct;71(10):2902-8. doi: 10.1093/jac/dkw247. Epub 2016 Jul 7.

PMID:
27402005
44.

Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis.

Zhanel GG, Walkty AJ, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2016;2016:2082693. doi: 10.1155/2016/2082693. Epub 2016 May 10. Review.

45.

Activity of Dapsone versus Community and Hospital Pathogens from the CANWARD Study.

Zhanel GG, Del Rosso JQ.

J Clin Aesthet Dermatol. 2016 Mar;9(3):42-7. Epub 2016 Mar 1. Review.

46.

Invasive Streptococcus pneumoniae in Canada, 2011-2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F.

Golden AR, Adam HJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Vaccine. 2016 May 17;34(23):2527-30. doi: 10.1016/j.vaccine.2016.03.058. Epub 2016 Apr 13.

PMID:
27085174
47.
48.

Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.

Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty A, Gin AS, Hoban DJ, Karlowsky JA.

Drugs. 2016 Apr;76(5):567-88. doi: 10.1007/s40265-016-0545-8. Review.

PMID:
26863149
49.

Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection.

Zhanel GG, Walkty AJ, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2015 Nov-Dec;26(6):305-12. Review.

50.

Adjuvants Based on Hybrid Antibiotics Overcome Resistance in Pseudomonas aeruginosa and Enhance Fluoroquinolone Efficacy.

Gorityala BK, Guchhait G, Fernando DM, Deo S, McKenna SA, Zhanel GG, Kumar A, Schweizer F.

Angew Chem Int Ed Engl. 2016 Jan 11;55(2):555-9. doi: 10.1002/anie.201508330. Epub 2015 Nov 26.

PMID:
26610184

Supplemental Content

Loading ...
Support Center